In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Data boom to data shroom: Mycelium could one day be data storage
In Ohio, scientists at Ohio State University have shown that mushroom mycelium can act as a form of data storage. In controlled lab experiments,...
Wooden compass points dementia patients back home
In the Netherlands, a startup has unveiled a device for dementia patients that is comprised of a single arrow that points to only one...
Snack to the future: Nutri3D wants to 3D print your next sweet treat
In Italy, researchers in the Nutri3D project have unveiled prototypes of nutrient-rich sweet snacks made from cultured plant cells, fruit byproducts, and 3D printing....